Streetbeat News

SXTP

60 Degrees Pharmaceuticals, Inc.

Industry

Biotechnology

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Open

1.07

Mkt cap

1.8M

Volume

93K

High

1.08

P/E Ratio

-0.62

52-wk high

18.36

Low

0.94

Div yield

N/A

52-wk low

0.70

HC Wainwright & Co. analyst Edward White has reiterated a Neutral rating on 60 Degrees (NASDAQ:SXTP).

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 1:14 pm

The article highlights the pre-market movements of various health care stocks on Thursday. Significant gainers include Aethlon Medical (AEMD), Virax Biolabs Group (VRAX), and iSpecimen (ISPC), while notable losers include Fresh2 Group (FRES), Renalytix (RNLX), and Masimo (MASI).

Portfolio Pulse from Benzinga Insights

June 06, 2024 | 12:07 pm

60 Degrees Pharmaceuticals has partnered with Tufts Medical Center to conduct the first clinical trial evaluating tafenoquine for treating babesiosis in humans. Enrollment will start on June 13, 2024, in Boston, with plans to expand recruitment to other hospitals in the Northeast U.S.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:01 pm

The article highlights significant intraday movements in health care stocks on Tuesday. Sharps Technology, Insmed, and Calliditas Therapeutics saw substantial gains, while Applied DNA Sciences, Innovative Eyewear, and Summit Therapeutics experienced notable declines.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 4:31 pm

The article highlights the performance of 12 healthcare stocks during Friday's after-market session. Sharps Technology (STSS) saw the highest gain with a 50.5% increase, while DIH Holding US (DHAI) experienced the largest drop, falling 24.4%.

Portfolio Pulse from Benzinga Insights

May 24, 2024 | 8:31 pm

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Notable gainers include SINTX Techs (SINT), Petros Pharma (PTPI), and Bluejay Diagnostics (BJDX). Significant losers include Eyenovia (EYEN), Lucy Scientific Discovery (LSDI), and Monte Rosa Therapeutics (GLUE).

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 8:32 pm

60 Degrees (NASDAQ:SXTP) reported a significant improvement in its Q1 earnings, with EPS rising to $0.03 from a loss of $(1.13) per share YoY. Sales also increased to $80.66K from $(51.66K) YoY.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 5:51 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Tevogen Bio Holdings led the gainers with a 55.4% increase, while Applied DNA Sciences experienced the largest drop among the losers at 13.1%. Earnings reports were a common factor influencing stock movements, with companies like Dynatronics, Tarsus Pharmaceuticals, Fulcrum Therapeutics, and Fortrea Holdings recently releasing their financial results.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 12:06 pm

60 Degrees Pharmaceuticals has announced the publication of a study titled 'Trial Planned to Evaluate Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Babesiosis Patients' in The Journal of Infectious Diseases. This publication marks a significant step in the research and development of treatments for Babesiosis, a disease caused by Babesia parasites. The study aims to assess the safety and efficacy of a combination treatment involving Tafenoquine and Atovaquone/Azithromycin in hospitalized patients suffering from this condition.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 12:00 pm

60 Degrees Pharmaceuticals has received feedback from the FDA regarding its clinical trial protocol for Tafenoquine-Babesiosis, indicating no material changes are required. This allows the trial planning and execution to proceed as planned.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.